News & Updates

Ketone supplements containing β-hydroxybutyrate yield potential neurocognitive benefits in individuals with obesity, specifically bolstering cognitive function and increasing cerebral blood flow, as reported in a recent study.

The antiviral monoclonal antibodies casirivimab-imdevimab appear to reduce the risk of hospitalization in patients with nonsevere COVID-19, as do bamlanivimab, bamlanivimab-etesevimab, and sotrovimab, according to the results of a systematic review and meta-analysis.

The humanized immunoglobulin G1 monoclonal antibody risankizumab conferred long-term benefit for individuals with active psoriatic arthritis (PsA) who had inadequate responses to biologic and conventional synthetic DMARDs* (csDMARDs), according to the open-label extension (OLE) phase findings of the KEEPsAKE 1 and 2 trials presented at EADV 2021.

Triplet therapy combining androgen deprivation therapy (ADT), docetaxel, and abiraterone-prednisone improves overall survival (OS) in men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to results of the phase III PEACE-1 trial presented at ESMO 2021.

Treatment with the novel, selective peroxisome proliferator-activated receptor α modulator (SPPARMα) pemafibrate appears to produce a significant reduction in liver stiffness but not in liver fat content in patients with high-risk nonalcoholic fatty liver disease (NAFLD), according to the results of a phase II trial.

In men with prostate cancer and concomitant atherosclerotic cardiovascular disease (ASCVD), major adverse cardiovascular event (MACE) incidence did not differ between those who were treated with degarelix or leuprolide, according to findings of the PRONOUNCE trial.

In individuals with type 2 diabetes (T2D), the glucagon-like peptide-1 receptor agonist (GLP1-RA) liraglutide appeared to yield a cardioprotective benefit, data from the secondary endpoint analysis of the LIRAFLAME* trial suggests.